share_log

EFFECT: Others

SEC ·  Oct 7, 2024 18:03

Summary by Futu AI

NeuroSense Therapeutics Ltd., a company listed in the United States, has received a Notice of Effectiveness from the Securities and Exchange Commission (SEC) on October 4, 2024. The notice, bearing the accession number 0001213900-24-083478, indicates that the company's submission type POS AM has been officially accepted. The CIK number associated with NeuroSense Therapeutics is 0001875091, and the SEC file number for this notice is 333-273375.
NeuroSense Therapeutics Ltd., a company listed in the United States, has received a Notice of Effectiveness from the Securities and Exchange Commission (SEC) on October 4, 2024. The notice, bearing the accession number 0001213900-24-083478, indicates that the company's submission type POS AM has been officially accepted. The CIK number associated with NeuroSense Therapeutics is 0001875091, and the SEC file number for this notice is 333-273375.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.